Guillermo Gervasini1, Carlos Jara2, Clara Olier2, Nuria Romero2, Ruth Martínez2, Juan Antonio Carrillo1. 1. Department of Medical and Surgical Therapeutics, Division of Clinical Pharmacology, Medical School, University of Extremadura, Alcorcón, Madrid, Spain. 2. Medical Oncology Department, Fundación Alcorcón University Hospital, Alcorcón, Madrid, Spain.
Abstract
AIMS: Anastrozole, an aromatase inhibitor widely used in breast cancer, has recently been indicated to be a P-glycoprotein (ABCB1) substrate. We have aimed to determine whether ABCB1 single-nucleotide polymorphisms (SNPs) can affect anastrozole plasma concentrations in these patients. In addition, we assessed the impact of SNPs in CYP19A1 and TCL1A on the development of arthralgia and cancer recurrence in our series. METHODS: This study included 110 postmenopausal women with hormone receptor-positive breast cancer. Anastrozole plasma levels were determined by a liquid chromatography-electrospray ionization-quadrupole-time-of-flight mass spectrometry system. Patients were genotyped for SNPs in the ABCB1, TCL1A and CYP19A1 genes to search for associations with pharmacokinetic and pharmacodynamics parameters using logistic regression models. RESULTS: Anastrozole concentrations showed an almost nine-fold interindividual variability (mean 26.95 ± 11.91 ng ml-1 ). The ABCB1 2677-TT genotype was associated with higher plasma levels (32.22 ± 12.82 vs. 25.86 ± 11.56 ng ml-1 for GG/GT subjects; 95% confidence interval: -12.3 to -0.40), whilst the 3435-TT genotype showed a protective effect on the risk of arthralgia (odds ratio = 0.32 [0.11-0.89]; P = 0.029). The CYP19A1 rs1008805 GG genotype was strongly and inversely associated with arthralgia (odds ratio = 0.24 [0.09-0.65], P = 0.004); however, SNPs near the TCL1A gene were not linked to this adverse effect. None of the patients who had cancer recurrence harboured the CYP19A1 rs727479 AA genotype, which, in contrast, was present in 38% of patients who did not relapse (P for trend = 0.031). CONCLUSION: Our findings indicate that variability in anastrozole plasma levels may be attributable to the status of the ABCB1 gene locus. Furthermore, genetic variants in CYP19A1 were associated with arthralgia and cancer recurrence in our patients.
AIMS: Anastrozole, an aromatase inhibitor widely used in breast cancer, has recently been indicated to be a P-glycoprotein (ABCB1) substrate. We have aimed to determine whether ABCB1 single-nucleotide polymorphisms (SNPs) can affect anastrozole plasma concentrations in these patients. In addition, we assessed the impact of SNPs in CYP19A1 and TCL1A on the development of arthralgia and cancer recurrence in our series. METHODS: This study included 110 postmenopausal women with hormone receptor-positive breast cancer. Anastrozole plasma levels were determined by a liquid chromatography-electrospray ionization-quadrupole-time-of-flight mass spectrometry system. Patients were genotyped for SNPs in the ABCB1, TCL1A and CYP19A1 genes to search for associations with pharmacokinetic and pharmacodynamics parameters using logistic regression models. RESULTS:Anastrozole concentrations showed an almost nine-fold interindividual variability (mean 26.95 ± 11.91 ng ml-1 ). The ABCB1 2677-TT genotype was associated with higher plasma levels (32.22 ± 12.82 vs. 25.86 ± 11.56 ng ml-1 for GG/GT subjects; 95% confidence interval: -12.3 to -0.40), whilst the 3435-TT genotype showed a protective effect on the risk of arthralgia (odds ratio = 0.32 [0.11-0.89]; P = 0.029). The CYP19A1rs1008805 GG genotype was strongly and inversely associated with arthralgia (odds ratio = 0.24 [0.09-0.65], P = 0.004); however, SNPs near the TCL1A gene were not linked to this adverse effect. None of the patients who had cancer recurrence harboured the CYP19A1rs727479 AA genotype, which, in contrast, was present in 38% of patients who did not relapse (P for trend = 0.031). CONCLUSION: Our findings indicate that variability in anastrozole plasma levels may be attributable to the status of the ABCB1 gene locus. Furthermore, genetic variants in CYP19A1 were associated with arthralgia and cancer recurrence in our patients.
Authors: James N Ingle; Aman U Buzdar; Daniel J Schaid; Matthew P Goetz; Anthony Batzler; Mark E Robson; Donald W Northfelt; Janet E Olson; Edith A Perez; Zeruesenay Desta; Randy A Weintraub; Clark V Williard; David A Flockhart; Richard M Weinshilboum Journal: Cancer Res Date: 2010-03-30 Impact factor: 12.701
Authors: Daniel L Hertz; William E Barlow; Kelley M Kidwell; Kathy S Albain; Ted A Vandenberg; Shaker R Dakhil; Nagendra R Tirumali; Robert B Livingston; Julie Gralow; Daniel F Hayes; Gabriel N Hortobagyi; Rita S Mehta; James M Rae Journal: Br J Clin Pharmacol Date: 2016-04-08 Impact factor: 4.335
Authors: Mitch Dowsett; Jack Cuzick; Jim Ingle; Alan Coates; John Forbes; Judith Bliss; Marc Buyse; Michael Baum; Aman Buzdar; Marco Colleoni; Charles Coombes; Claire Snowdon; Michael Gnant; Raimund Jakesz; Manfred Kaufmann; Francesco Boccardo; Jon Godwin; Christina Davies; Richard Peto Journal: J Clin Oncol Date: 2009-11-30 Impact factor: 44.544
Authors: Daniel L Hertz; Julie A Douglas; Robert M Miller; Kelley M Kidwell; Christina L Gersch; Zeruesenay Desta; Anna Maria Storniolo; Vered Stearns; Todd C Skaar; Daniel F Hayes; N Lynn Henry; James M Rae Journal: Support Care Cancer Date: 2022-07-01 Impact factor: 3.359
Authors: Raquel E Reinbolt; Stephen Sonis; Cynthia D Timmers; Juan Luis Fernández-Martínez; Ana Cernea; Enrique J de Andrés-Galiana; Sepehr Hashemi; Karin Miller; Robert Pilarski; Maryam B Lustberg Journal: Cancer Med Date: 2017-11-23 Impact factor: 4.452
Authors: Helga Tryggvadottir; Emma Sandén; Sofie Björner; Alessandra Bressan; Maria Ygland Rödström; Somayeh Khazaei; Dean P Edwards; Björn Nodin; Karin Jirström; Karolin Isaksson; Signe Borgquist; Helena Jernström Journal: Front Oncol Date: 2021-05-20 Impact factor: 6.244
Authors: Elizabeth Cathcart-Rake; Paul Novotny; Roberto Leon-Ferre; Jennifer Le-Rademacher; Elizabeth M Storrick; Araba A Adjei; Shelby Terstriep; Rebecca Glaser; Armando Giuliano; William R Mitchell; Seth Page; Colleen Austin; Richard L Deming; Margaret A Ferreira; Jacqueline M Lafky; Stephen N Birrell; Charles L Loprinzi Journal: Support Care Cancer Date: 2020-05-06 Impact factor: 3.359